CytoDyn Presents Updated Leronlimab Data in Metastatic Colorectal Cancer at ESMO Congress 2026
CytoDyn presented updated Phase 2 CLOVER study data for leronlimab in metastatic colorectal cancer at the ESMO Congress 2026 in Madrid. The 66-patient study showed CCR5 expression in 100% of evaluable tumor samples, a median 86% ctDNA reduction at Week 2, and no leronlimab-related adverse events above Grade 2 or treatment discontinuations. The combination with TFD/TPI plus bevacizumab showed significantly deeper molecular residual disease reductions versus control arms (p=0.0005 and p=0.0006).
Key figures
- Drug Name
- leronlimab
- Phase Of Trial
- Phase 2
- Clinical sites
- 7
- Patients enrolled
- 66
- Ccr5 expression rate
- 100% (91/91 evaluable archival tumor samples)
- Safety data patients
- 32
- Mrd reduction p values
- 0.0005 (0-4 weeks) vs TFD/TPI+BEV, 0.0006 (0-8 weeks)
- Median ctdna reduction week2
- 86% (n=28)
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.